Literature DB >> 20872595

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Daniel Aletaha1, Tuhina Neogi, Alan J Silman, Julia Funovits, David T Felson, Clifton O Bingham, Neal S Birnbaum, Gerd R Burmester, Vivian P Bykerk, Marc D Cohen, Bernard Combe, Karen H Costenbader, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Johanna M W Hazes, Kathryn Hobbs, Tom W J Huizinga, Arthur Kavanaugh, Jonathan Kay, Tore K Kvien, Timothy Laing, Philip Mease, Henri A Ménard, Larry W Moreland, Raymond L Naden, Theodore Pincus, Josef S Smolen, Ewa Stanislawska-Biernat, Deborah Symmons, Paul P Tak, Katherine S Upchurch, Jirí Vencovský, Frederick Wolfe, Gillian Hawker.   

Abstract

OBJECTIVE: The 1987 American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA.
METHODS: A joint working group from the ACR and the European League Against Rheumatism developed, in 3 phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease--this being the appropriate current paradigm underlying the disease construct "rheumatoid arthritis."
RESULTS: In the new criteria set, classification as "definite RA" is based on the confirmed presence of synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0-5), serologic abnormality (score range 0-3), elevated acute-phase response (score range 0-1), and symptom duration (2 levels; range 0-1).
CONCLUSION: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimize the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct "rheumatoid arthritis."

Entities:  

Mesh:

Year:  2010        PMID: 20872595     DOI: 10.1002/art.27584

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  2000 in total

1.  Validity and interpretability of the QuickDASH in the assessment of hand disability in rheumatoid arthritis.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Sonia Farah
Journal:  Rheumatol Int       Date:  2018-12-03       Impact factor: 2.631

2.  [Higher prevalence of depressive and anxiety symptoms in early arthritis patients in comparison to the normal population].

Authors:  D Freier; M Englbrecht; V Höhne-Zimmer; J Detert; G-R Burmester
Journal:  Z Rheumatol       Date:  2019-11       Impact factor: 1.372

3.  MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.

Authors:  Ankita Singh; Pradeepta Sekhar Patro; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2018-12-03       Impact factor: 2.980

4.  Intra-individual assessment of inflammatory severity and cartilage composition of finger joints in rheumatoid arthritis.

Authors:  C Schleich; A Müller-Lutz; P Sewerin; B Ostendorf; C Buchbender; M Schneider; G Antoch; F Miese
Journal:  Skeletal Radiol       Date:  2014-11-01       Impact factor: 2.199

Review 5.  [Molecular pathological diagnostics of infections in orthopedic pathology].

Authors:  J Kriegsmann; N Arens; C Altmann; M Kriegsmann; R Casadonte; M Otto
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

6.  Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis.

Authors:  Alvin Yee; Tyler Webb; Andrea Seaman; Maria Infantino; Francesca Meacci; Mariangela Manfredi; Maurizio Benucci; Gabriella Lakos; Ennio Favalli; Tommaso Schioppo; Tommaso Shioppo; Pier-Luigi Meroni; Michael Mahler
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

7.  Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.

Authors:  Jinqiu Yuan; Changhua Zhang; Jeffrey A Sparks; Susan Malspeis; Kelvin Kam-Fai Tsoi; Jean H Kim; Benjamin A Fisher; Fang Gao; Tim Sumerlin; Yan Liu; Yuxing Liu; Yihang Pan; Yulong He; Joseph J Y Sung
Journal:  Aliment Pharmacol Ther       Date:  2020-06-29       Impact factor: 8.171

8.  Health-related quality of life in midlife women in Qatar: relation to arthritis and symptoms of joint pain.

Authors:  Linda M Gerber; Ya-Lin Chiu; Mohamud Verjee; Hassan Ghomrawi
Journal:  Menopause       Date:  2016-03       Impact factor: 2.953

9.  [Immune diagnostics in rheumatology].

Authors:  R Gruber; S Borgmann
Journal:  Z Rheumatol       Date:  2014-08       Impact factor: 1.372

10.  Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease.

Authors:  Chase S Correia; Melissa R Briones; Rong Guo; Rochella A Ostrowski
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.